Invigo Therapeutics SRL
Invigo Therapeutics reported total assets of 2,055 € at the end of the 2026 financial year (annual accounts filed with the NBB on 28 Sep 2026).
The score of Invigo Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2024 → 2026: Equity -79 % Total assets -89 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Invigo Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 28 Sep 2026
- Year ended 31 Mar 2025filed on 31 Oct 2025
- Year ended 31 Mar 2024filed on 30 Sep 2024
Invigo Therapeutics's financial analysis
- Solvency100.0%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Invigo Therapeutics
Invigo Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0789.481.317
- VAT number
- BE0789481317
- Peppol
- Registered · 0208:0789481317 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Aug 2022
- Registered office
- 2800 Mechelen
- Latest accounts
- 2026 · filed on 28 Sep 2026
- Activity
- Manufacture of other pharmaceutical products (NACE 21209)
Invigo Therapeutics (SRL) has been based in Mechelen since 2022, active in: manufacture of other pharmaceutical products. For 2026, it reports a net profit of 9,011 € and equity of 2,055 €; its revenue is not published. Its solvency stands at 100.0%, above the median of its sector (47.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Invigo Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Apcor R&M Manufacture of basic pharmaceutical products Ghent · balance sheet 5,677 €
- Raya Therapeutic Manufacture of basic pharmaceutical products Leuven · balance sheet 5,330 €
- OncoRNA Research and experimental development on natural sciences and engineering Charleroi · balance sheet 20,034 €
- RheADC Manufacture of basic pharmaceutical products Leuven · balance sheet 31,395 €
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- MC Pharma Manufacture of basic pharmaceutical products Beaumont · balance sheet 28,699 €
- Biomdrin Manufacture of pharmaceutical preparations Schilde · balance sheet 38,268 €
- Attito Management Manufacture of pharmaceutical preparations Kapelle-op-den-Bos · balance sheet 131,498 €
Frequently asked questions about Invigo Therapeutics
What is the revenue of Invigo Therapeutics?
Invigo Therapeutics files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Invigo Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0789481317 for Invigo Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0789.481.317.
Where is the registered office of Invigo Therapeutics?
According to the CBE register, the registered office of Invigo Therapeutics is in 2800 Mechelen.
What is the equity of Invigo Therapeutics?
At the close of the 2026 financial year, the equity of Invigo Therapeutics amounts to 2,055 €, a solvency of 100.0% of total assets.
Who manages Invigo Therapeutics?
The register lists 2 active mandates at Invigo Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Invigo Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →